Polyethylene Glycol 3350
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MIRALAX | — | 2009-03-13 | fda.gov ↗ |
| Approved | US (FDA) | GOLYTELY | — | 1984-07-13 | fda.gov ↗ |
Trials 57
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07700277 | Aug 2026 → Aug 2027 expected | intestinal disorder | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03236064 | May 2016 → May 2024 | nervous system injury | WellSpan Health | Unknown | No outcome recorded |
| Phase 1 | NCT01834742 | Apr → Sep 2011 | colorectal cancer | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00868985 | Jan → Aug 2008 | constipation disorder | Norgine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04270019 | Jun 2020 → Sep 2023 | nervous system injury, peripheral nerve lesion | Nova Scotia Health Authority | Withdrawn | No outcome recorded |
| Phase 26 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT03332485 | Nov 2017 → Mar 2018 | — | Sebela Pharmaceuticals Development LLC | Completed | No outcome recorded |
| Phase 2 | NCT02910440 | Jan → Nov 2017 | — | Dark Canyon Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01714466 | Oct 2012 → Jul 2013 | colon carcinoma | Norgine | Completed | Met primary |
| Phase 2 | NCT01212445 | Oct 2010 → Nov 2011 | constipation disorder | Bayer | Completed | Missed primary |
| Phase 2 | NCT00828984 | Oct 2009 → Oct 2014 | adenoma, colorectal carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00403858 | Oct 2000 → Apr 2002 | intestinal impaction | Norgine | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05897086 | Aug 2023 → Dec 2028 expected | — | Vanderbilt University Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 313 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT03957668 | Dec 2019 → Sep 2020 | constipation disorder | Faculty of Medicine, University of Indonesia | Unknown | No outcome recorded |
| Phase 3 | NCT03106922 | Apr 2016 → Jul 2020 | — | Alfasigma S.p.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02292459 | Dec 2015 | constipation disorder | Bayer | Withdrawn | No outcome recorded |
| Phase 3 | NCT02540031 | Sep 2015 → Apr 2018 | — | Kyungpook National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02273141 | Nov 2014 → Aug 2015 | colorectal carcinoma | Norgine | Completed | Missed primary |
| Phase 3 | NCT02273167 | Oct 2014 → Aug 2015 | colorectal carcinoma | Norgine | Completed | Mixed |
| Phase 3 | NCT02254486 | Sep 2014 → Jun 2015 | colon carcinoma | Norgine | Completed | Missed primary |
| Phase 3 | NCT01929590 | Oct 2011 → Jun 2012 | — | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | No outcome recorded |
| Phase 3 | NCT01251822 | Nov 2010 → Sep 2011 | constipation disorder | Norgine | Completed | Met primary |
| Phase 3 | NCT00503607 | Jul → Nov 2007 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00503815 | Jul → Nov 2007 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00403819 | Apr 2002 → Apr 2003 | constipation disorder | Norgine | Completed | No outcome recorded |
| Phase 3 | NCT00403897 | Aug 2001 → Jan 2003 | constipation disorder | Norgine | Completed | No outcome recorded |
| Phase 425 trials · 3 met primary · 2 missed | ||||||
| Phase 4 | NCT06159777 | Jun 2024 → Mar 2026 | constipation disorder, pelvic organ prolapse | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05821309 | Jun 2023 → Jul 2026 overdue | constipation disorder | Indiana University | Recruiting | No outcome recorded |
| Phase 4 | NCT05805436 | Jun 2023 → Mar 2026 overdue | constipation disorder, kidney cancer, prostate cancer | Chad R. Tracy | Recruiting | No outcome recorded |
| Phase 4 | NCT04708366 | Feb 2021 → Mar 2022 | colonic disorder | University of Bologna | Unknown | No outcome recorded |
| Phase 4 | NCT04585542 | Oct 2020 → Jan 2025 | — | University of California, Irvine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04210427 | Dec 2019 → Jun 2023 | cystic fibrosis | St. Louis University | Completed | No outcome recorded |
| Phase 4 | NCT04197869 | Dec 2019 → Jun 2023 | constipation disorder | Northwell Health | Completed | Missed primary |
| Phase 4 | NCT04263896 | Aug 2019 → Jun 2024 | constipation disorder | University of Chicago | Completed | No outcome recorded |
| Phase 4 | NCT03800745 | Nov 2018 → May 2020 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03742232 | Oct 2018 → Mar 2020 | colon adenoma, polyp of colon | Istituto Clinico Humanitas | Completed | Met primary |
| Phase 4 | NCT03987893 | May 2018 → May 2020 | hepatic encephalopathy, liver disorder | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT02290093 | Nov 2014 → Sep 2015 | — | Kyunghee University Medical Center | Completed | Met primary |
| Phase 4 | NCT02073552 | May 2014 → Dec 2015 | — | Fundación Canaria Rafael Clavijo para la Investigación Biomédica | Completed | Missed primary |
| Phase 4 | NCT01719653 | Oct 2012 → Sep 2014 | — | Gastroenterology Services, Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01429779 | Jul 2012 → Oct 2014 | liver disorder | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01063049 | Feb 2010 → Feb 2011 | — | Gastroenterology Services, Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00889655 | May 2009 → May 2010 | — | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 4 | NCT00583609 | Sep 2007 → Jul 2008 | constipation disorder | Braintree Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00319670 | Mar → May 2006 | constipation disorder | Braintree Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00171522 | May → Sep 2005 | constipation disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00153140 | Jul → Oct 2004 | constipation disorder | Braintree Laboratories | Completed | Met primary |
| Phase 4 | NCT00153153 | Aug 2003 → Dec 2004 | constipation disorder | Braintree Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00164125 | Jul 2003 → Nov 2004 | constipation disorder | Braintree Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00153114 | Jan 2003 → Sep 2004 | constipation disorder | Braintree Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT00153127 | Nov 2001 → Sep 2004 | constipation disorder | Braintree Laboratories | Completed | No outcome recorded |
| Phase not applicable7 trials · 1 missed | ||||||
| — | NCT05726344 | Feb → Dec 2023 | — | Hospital de Clínicas Dr. Manuel Quintela | Completed | No outcome recorded |
| — | NCT01717456 | Jan 2013 → Mar 2015 | — | University of North Carolina, Chapel Hill | Terminated | Missed primary Stop: Enrollment |
| — | NCT01452737 | Nov 2011 → May 2012 | — | University of British Columbia | Withdrawn | No outcome recorded |
| — | NCT01518790 | Sep 2010 → Aug 2011 | — | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| — | NCT01299779 | Jun 2010 → May 2012 | — | Thomas Jefferson University | Completed | No outcome recorded |
| — | NCT01044212 | Nov 2009 → Feb 2011 | intestinal disorder | University of Rochester | Completed | No outcome recorded |
| — | NCT01028573 | Nov 2009 → Jul 2012 | — | Southern California Institute for Research and Education | Unknown | No outcome recorded |
| Comparator or background therapy42 trials | ||||||
| Phase 0 | NCT07604025 Comparator | Jul 2026 → Jul 2027 expected | constipation disorder | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT00765557 Comparator | Dec 2007 → Jun 2014 | constipation disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT06393400 Background | Jan 2025 → Feb 2028 expected | pancreatic ductal adenocarcinoma | John Lenehan | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02272868 Background | Jan 2015 → Oct 2016 | Crohn disease | Seattle Children's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT06503978 Background | Aug 2024 → Jul 2025 overdue | autism spectrum disorder, constipation disorder, diarrheal disease | Gut-Brain-Axis Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04182633 Background | Nov 2019 → Feb 2025 overdue | autism spectrum disorder, constipation disorder, diarrheal disease | Arizona State University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03476317 Background | Jul 2018 → Dec 2020 | Crohn disease | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT02765256 Background | Aug 2016 → Dec 2018 | Crohn disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02402270 Comparator | May 2015 → Jun 2016 | — | ColonaryConcepts LLC | Completed | No outcome recorded |
| Phase 2/3 | NCT06836024 Comparator | Jun 2025 → Dec 2026 expected | constipation disorder | Hamilton Health Sciences Corporation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01501513 Comparator | Dec 2011 → Mar 2013 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00856843 Comparator | Feb → May 2009 | — | Braintree Laboratories | Completed | Met primary |
| Phase 3 | NCT00756548 Comparator | Aug → Nov 2008 | colon carcinoma | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00756977 Comparator | Aug → Nov 2008 | colon carcinoma | Braintree Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT07351019 Comparator | Jan → Jul 2026 overdue | colorectal cancer | Eisenhower Army Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07215000 Comparator | Oct 2025 → Jan 2027 expected | colorectal cancer | Morehouse School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06825260 Comparator | Apr 2025 → Mar 2027 expected | outlet dysfunction constipation | St. Joseph's Health, New York | Recruiting | No outcome recorded |
| Phase 4 | NCT06455813 Comparator | Oct 2024 → Jan 2027 expected | — | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07605897 Comparator | Nov 2022 → Jun 2025 | colorectal cancer | Joseph Spataro | Completed | No outcome recorded |
| Phase 4 | NCT02337413 Comparator | Jun → Jul 2020 | nocturnal enuresis | Rabin Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02336906 Comparator | Jan → Jul 2020 | enuresis | Rabin Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03298945 Comparator | Dec 2018 → Dec 2023 | colorectal cancer | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT03198221 Comparator | Jul 2018 → Mar 2019 | — | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03148002 Comparator | Jul 2017 → Apr 2018 | constipation disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 4 | NCT03060512 Comparator | Mar → Aug 2017 | opioid-induced constipation | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT03177434 Comparator | Feb 2016 → May 2018 | constipation disorder | Children's Memorial Health Institute, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT01773096 Background | May 2013 → May 2015 | constipation disorder | Shriners Hospitals for Children | Completed | No outcome recorded |
| Phase 4 | NCT01707667 Comparator | Feb → Nov 2013 | constipation disorder | Shire | Completed | Met primary |
| Phase 4 | NCT01169220 Comparator | Jul 2010 → Jan 2014 | colorectal cancer | Santa Clara Valley Health & Hospital System | Completed | No outcome recorded |
| Phase 4 | NCT01170754 Comparator | Apr 2010 → Jul 2011 | colorectal cancer | Temple University | Completed | No outcome recorded |
| Phase 4 | NCT00953017 Comparator | Jul 2009 → May 2010 | — | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00770432 Comparator | Nov 2007 → Jan 2008 | constipation disorder | Bayer | Completed | No outcome recorded |
| — | NCT05318365 Comparator | Sep 2022 → Dec 2025 | BD syndrome | University of Aarhus | Unknown | No outcome recorded |
| — | NCT04504292 Comparator | Aug 2020 → May 2021 | — | University of Virginia | Unknown | No outcome recorded |
| — | NCT03011788 Comparator | Jan 2017 → Dec 2020 | — | VA Connecticut Healthcare System | Unknown | No outcome recorded |
| — | NCT02124447 Comparator | Jun → Aug 2014 | — | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| — | NCT01566409 Comparator | Sep 2013 → Apr 2015 | constipation disorder | Line Modin | Completed | No outcome recorded |
| — | NCT01978509 Comparator | Sep 2013 → Mar 2019 | — | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01923376 Comparator | Feb 2013 → Feb 2014 | cirrhosis of liver, hepatic encephalopathy | New York Presbyterian Brooklyn Methodist Hospital | Withdrawn | No outcome recorded |
| — | NCT01691742 Comparator | Sep 2012 → Mar 2015 | constipation disorder | Duke University | Completed | No outcome recorded |
| — | NCT01533688 Comparator | Oct 2011 → Oct 2016 | diabetes mellitus | University of Oklahoma | Completed | No outcome recorded |
| — | NCT00467350 Comparator | Dec 2006 → May 2009 | constipation disorder | Children's Mercy Hospital Kansas City | Terminated | No outcome recorded |
Press releases naming this drug 13 releases
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 106 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polyethylene glycol 3350 | “This multicenter, double-blind, placebo-controlled, parallel-group trial included adults with chronic idiopathic constipation randomized to polyethylene glycol 3350 17 g...” PMID 36120087 ↗ Sep 202243“OBJECTIVES: The aim of this study was to compare the clinical efficacy and tolerance of polyethylene glycol 3350 (PEG) and lactulose for the treatment of functional...” PMID 30383579 ↗ Mar 2019 “This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer.” NCT00828984 ↗ “To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.” NCT00319670 ↗ “Two common treatments are polyethylene glycol 3350 (PEG), an osmotic laxative, and Senna, a plant-based stimulant laxative.” NCT07604025 ↗ “Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration.” NCT04197869 ↗ “Patients will receive the Protocol with Polyethylene Glycol 3350.” NCT03148002 ↗ “PEG 3350 (polyethylene glycol 3350)” NCT03957668 ↗ |
| Known as | BAY81-8430 | “PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)” NCT01212445 ↗ |
| Known as | Golytely | “1. Split dose 4 liter polyethylene glycol with electrolytes (PEG+E): Brand name GoLytely” NCT02124447 ↗17“Subjects will be asked to take 4L of Golytely the day prior to procedure.” NCT01452737 ↗ “Polyethylene glycol 3350 - electrolyte solution (GoLYTELY)” NCT07605897 ↗ “Golytely (polyethylene glycol)” NCT00953017 ↗ “Drug: Go Lytely” NCT01169220 ↗ “Drug: Golytely” NCT07215000 ↗ |
| Known as | Golytely Oral Product | “Drug: Golytely Oral Product” NCT04504292 ↗ |
| Known as | LVPEG-4 | “Named NER1006, LVPEG-4 demonstrated clinical proof of concept and warrants further investigation.” PMID 31146679 ↗ May 2019 |
| Known as | Macrogol | “Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in” PMID 23480216 ↗ Mar 20131“PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)” NCT01212445 ↗ |
| Known as | Macrogol 3350 | “macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.” NCT03106922 ↗3“One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride.” NCT01429779 ↗ |
| Known as | Macrogol 3350 and electrolytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06455813 ↗ |
| Known as | MiraLax | “Polyethylene glycol (PEG) 3350 (MiraLax) and tegaserod (Zelnorm), a serotonin subtype 4 receptor partial agonist, are currently approved for treatment of constipation.” PMID 17573794 ↗ Jun 200717“Patients will be randomized to either receive or not receive three days of polyethylene glycol (PEG, also known as MiraLAX) on the three days before surgery.” NCT05805436 ↗ “All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.” NCT04210427 ↗ “Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber.” NCT01717456 ↗ “238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy” NCT01028573 ↗ “MiraLax (polyethylene glycol 3350)” NCT00889655 ↗ “Miralax 1 packet daily” NCT01044212 ↗ “Miralax (PEG 3350)” NCT00953017 ↗ |
| Known as | Miralax (polyethylene glycol) | “Miralax (polyethylene glycol)” NCT01717456 ↗ |
| Known as | Movicol | “The use of Macrogol (Movicol®) as laxative during one week prior to partial liver resection will further enhance early return of gastro-intestinal function and accelerate...” NCT01429779 ↗2“PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)” NCT01212445 ↗ “Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)” NCT00403858 ↗ |
| Known as | MoviPrep | “MoviPrep® (PEG 3350)” NCT02402270 ↗ |
| Known as | NER1006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04708366 ↗ |
| Known as | NuLYTELY | “NuLYTELY® (PEG 3350)” NCT02402270 ↗ |
| Known as | PEG | “Safety of polyethylene glycol (PEG) formulations has been validated in several studies, it presents little severe side effects and the advantage of its applicability to...” NCT05726344 ↗6“Polyethylene glycol (PEG) is a hydrophilic compound that enhances the fusion of the lipid bilayer membrane of severed axons, restoring the nerve's immediate ability to conduct...” NCT05897086 ↗ “Patients will be randomized to either receive or not receive three days of polyethylene glycol (PEG, also known as MiraLAX) on the three days before surgery.” NCT05805436 ↗ “All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.” NCT04210427 ↗ “Polyethylene glycol (PEG) 3350 electrolyte solution can ensure rapid gut catharsis, which may resolve HE more effectively than lactulose.” PMID 33060437 ↗ Jan 2022 “Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications” NCT00153127 ↗ “Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation.” NCT06159777 ↗ |
| Known as | PEG + E | “OBJECTIVES: To assess the efficacy of polyethylene glycol 3350 plus electrolytes (PEG + E; Movicol) as oral monotherapy in the treatment of faecal impaction in children, and to...” PMID 16819379 ↗ Jul 2006 |
| Known as | PEG 3350 | “Polyethylene glycol (PEG) 3350 (MiraLax) and tegaserod (Zelnorm), a serotonin subtype 4 receptor partial agonist, are currently approved for treatment of constipation.” PMID 17573794 ↗ Jun 200728“Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g” NCT02540031 ↗ “Eligible subjects ≥ 17 years of age were randomized to receive either placebo or PEG 3350 17 g once daily in this multicenter, double-blind trial.” PMID 27158544 ↗ May 2016 “Polyethylene glycol (PEG) 3350 electrolyte solution can ensure rapid gut catharsis, which may resolve HE more effectively than lactulose.” PMID 33060437 ↗ Jan 2022 “238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy” NCT01028573 ↗ “This study will evaluate the safety and efficacy of PEG 3350 for use in nerve repair.” NCT03236064 ↗ “Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.” NCT02290093 ↗ “a laxative, polyethylene glycol 3350 (PEG-3350) taken with 4 liters of water.” NCT07605897 ↗ “Polyethylene Glycol 3350 Powder for Solution (PEG 3350)” NCT02292459 ↗ “with PEG-3350 119 gram bottle (labeled #1)” NCT01299779 ↗ “ECP (PEG 3350) Colon Prep Kit” NCT03332485 ↗ |
| Known as | PEG 3350 with electrolytes | “split-dose (PEG) 3350 with electrolytes (GoLytely; Braintree Laboratories, Inc, Braintree, MA)” PMID 21115134 ↗ Nov 2010 |
| Known as | PEG 3350+E | “Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in” PMID 23480216 ↗ Mar 2013 |
| Known as | PEG-ELS-(GoLytely) | “4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy” NCT01533688 ↗ |
| Known as | PGE + E | “Treatment of faecal impaction with polyethelene glycol plus electrolytes (PGE + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy.” PMID 16819379 ↗ Jul 2006 |
| Known as | Polyethylene glycol | “Patients will be randomized to either receive or not receive three days of polyethylene glycol (PEG, also known as MiraLAX) on the three days before surgery.” NCT05805436 ↗3“Polyethylene glycol (PEG) 3350 electrolyte solution can ensure rapid gut catharsis, which may resolve HE more effectively than lactulose.” PMID 33060437 ↗ Jan 2022 “Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications” NCT00153127 ↗ “Golytely (polyethylene glycol)” NCT00953017 ↗ |
| Known as | Polyethylene Glycol (PEG) | “subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E)” NCT01212445 ↗ |
| Known as | polyethylene glycol (PEG) 3350 | “This study is to compare the efficacy and safety of polyethylene glycol (PEG) 3350 with that of prucalopride in the treatment of chronic constipation in females.” NCT01251822 ↗ |
| Known as | polyethylene glycol electrolyte lavage solution | “Golytely (polyethylene glycol electrolyte lavage solution) and placebo” NCT01533688 ↗ |
| Modality | Other / unclassified | “five new low-volume PEG-based bowel preparations (LVPEG) were tested for clinical proof of concept.” PMID 31146679 ↗ May 2019 |
| Route | Oral | “It allows a single orally administered laxative to be used for disimpaction without recourse to invasive interventions.” PMID 16819379 ↗ Jul 2006 |